Advertisement
Screener

Moleculin Biotech, Inc. (MBRX) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

Moleculin Biotech, Inc. Operating Expenses

Moleculin Biotech, Inc. (MBRX) reported Operating Expenses of $7.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-13

  • Moleculin Biotech, Inc. operating expenses for the quarter ending 2026-06-30 was $7.56M, a 32.19% increase year-over-year.
  • Moleculin Biotech, Inc. operating expenses for the quarter ending 2026-03-31 was $7.87M, a 32.49% increase year-over-year.
  • Moleculin Biotech, Inc. operating expenses for the quarter ending 2025-12-31 was $7.53M, a 13.40% increase year-over-year.
  • Moleculin Biotech, Inc. operating expenses for the quarter ending 2025-09-30 was $5.91M, a 17.22% decline year-over-year.
  • Moleculin Biotech, Inc. operating expenses for fiscal 2025 was $25.10M, a 5.77% decline from fiscal 2024.
  • Moleculin Biotech, Inc. operating expenses for fiscal 2024 was $26.64M, a 10.09% decline from fiscal 2023.
  • Moleculin Biotech, Inc. operating expenses for fiscal 2023 was $29.63M, a 3.29% decline from fiscal 2022.
  • Moleculin Biotech, Inc. operating expenses for fiscal 2022 was $30.64M, a 33.40% increase from fiscal 2021.
Period endOperating Expenses 2 monthOperating Expenses 3 monthOperating Expenses 3 month as first filedOperating Expenses 5 monthOperating Expenses 6 monthOperating Expenses 6 month as first filedOperating Expenses 9 monthOperating Expenses 9 month as first filedOperating Expenses 12 monthOperating Expenses 12 month as first filed
2026-06-30$7.56M
10-Q · filed 2026-08-13
$15.44M
10-Q · filed 2026-08-13
$22.97M
derived: sum of 3 quarters · filed 2026-08-13
$28.87M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$7.87M
10-Q · filed 2026-05-14
$15.41M
derived: sum of 2 quarters · filed 2026-05-14
$21.31M
derived: sum of 3 quarters · filed 2026-05-14
$27.03M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$7.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$13.44M
derived: sum of 2 quarters · filed 2026-03-18
$19.16M
derived: sum of 3 quarters · filed 2026-08-13
$25.10M
10-K · filed 2026-03-18
2025-09-30$5.91M
10-Q · filed 2025-11-13
$11.63M
derived: sum of 2 quarters · filed 2026-08-13
$17.57M
10-Q · filed 2025-11-13
$24.21M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$5.72M
10-Q · filed 2026-08-13
$11.66M
10-Q · filed 2026-08-13
$18.31M
derived: sum of 3 quarters · filed 2026-08-13
$25.44M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$5.94M
10-Q · filed 2026-05-14
$12.59M
derived: sum of 2 quarters · filed 2026-05-14
$19.72M
derived: sum of 3 quarters · filed 2026-05-14
$25.91M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31$6.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$13.78M
derived: sum of 2 quarters · filed 2026-03-18
$19.96M
derived: sum of 3 quarters · filed 2026-03-18
$26.64M
10-K · filed 2026-03-18
2024-09-30$7.13M
10-Q · filed 2025-11-13
$13.32M
derived: sum of 2 quarters · filed 2025-11-13
$20.00M
10-Q · filed 2025-11-13
$28.92M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$6.18M
10-Q · filed 2025-08-12
$12.86M
10-Q · filed 2025-08-12
$21.78M
derived: sum of 3 quarters · filed 2025-08-12
$27.73M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$6.68M
10-Q · filed 2025-05-13
$15.60M
derived: sum of 2 quarters · filed 2025-05-13
$21.54M
derived: sum of 3 quarters · filed 2025-05-13
$27.95M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$8.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21
$14.87M
derived: sum of 2 quarters · filed 2025-03-21
$21.28M
derived: sum of 3 quarters · filed 2025-03-21
$29.63M
10-K · filed 2025-03-21
2023-09-30$5.95M
10-Q · filed 2024-11-08
$12.36M
derived: sum of 2 quarters · filed 2024-11-08
$20.71M
10-Q · filed 2024-11-08
$27.76M
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30$6.41M
10-Q · filed 2024-08-13
$14.77M
10-Q · filed 2024-08-13
$21.81M
derived: sum of 3 quarters · filed 2024-08-13
$30.90M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$8.35M
10-Q · filed 2024-05-10
$15.40M
derived: sum of 2 quarters · filed 2024-05-10
$24.49M
derived: sum of 3 quarters · filed 2024-05-10
$31.92M
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31$7.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22
$16.13M
derived: sum of 2 quarters · filed 2024-03-22
$23.57M
derived: sum of 3 quarters · filed 2024-03-22
$30.64M
10-K · filed 2024-03-22
2022-09-30$9.08M
10-Q · filed 2023-11-13
$16.52M
derived: sum of 2 quarters · filed 2023-11-13
$23.59M
10-Q · filed 2023-11-13
$28.80M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$7.43M
10-Q · filed 2023-08-10
$14.51M
10-Q · filed 2023-08-10
$19.71M
derived: sum of 3 quarters · filed 2023-08-10
$25.87M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$7.07M
10-Q · filed 2023-05-10
$12.28M
derived: sum of 2 quarters · filed 2023-05-10
$18.44M
derived: sum of 3 quarters · filed 2023-05-10
$23.95M
derived: sum of 4 quarters · filed 2023-05-10
2021-12-31$5.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22
$11.36M
derived: sum of 2 quarters · filed 2023-03-22
$16.88M
derived: sum of 3 quarters · filed 2023-03-22
$22.97M
10-K · filed 2023-03-22
2021-09-30$6.16M
10-Q · filed 2022-11-10
$11.67M
derived: sum of 2 quarters · filed 2022-11-10
$17.76M
10-Q · filed 2022-11-10
$21.26M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$5.52M
10-Q · filed 2022-08-12
$11.61M
10-Q · filed 2022-08-12
$15.10M
derived: sum of 3 quarters · filed 2022-08-12
$21.25M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31$6.09M
10-Q · filed 2022-05-11
$9.58M
derived: sum of 2 quarters · filed 2022-05-11
$15.73M
derived: sum of 3 quarters · filed 2022-05-11
$20.77M
derived: sum of 4 quarters · filed 2022-05-11
2020-12-31$3.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24
$9.65M
derived: sum of 2 quarters · filed 2022-03-24
$14.68M
derived: sum of 3 quarters · filed 2022-03-24
$19.74M
10-K · filed 2022-03-24
2020-09-30$6.15M
10-Q · filed 2021-11-10
$11.19M
derived: sum of 2 quarters · filed 2021-11-10
$16.25M
10-Q · filed 2021-11-10
$21.06M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$5.03M
10-Q · filed 2021-08-11
$10.10M
10-Q · filed 2021-08-11
$14.91M
derived: sum of 3 quarters · filed 2021-08-11
$19.42M
derived: sum of 4 quarters · filed 2021-08-11
2020-03-31$5.06M
10-Q · filed 2021-05-12
$9.88M
derived: sum of 2 quarters · filed 2021-05-12
$14.38M
derived: sum of 3 quarters · filed 2021-05-12
$18.02M
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31$4.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24
$9.32M
derived: sum of 2 quarters · filed 2021-03-24
$12.95M
derived: sum of 3 quarters · filed 2021-03-24
$17.52M
10-K · filed 2021-03-24
2019-09-30$4.51M
10-Q · filed 2020-11-12
$8.14M
derived: sum of 2 quarters · filed 2020-11-12
$12.71M
10-Q · filed 2020-11-12
$17.05M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$3.63M
10-Q · filed 2020-08-12
$8.20M
10-Q · filed 2020-08-12
$12.54M
derived: sum of 3 quarters · filed 2020-08-12
$15.13M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31$4.57M
10-Q · filed 2020-05-11
$8.91M
derived: sum of 2 quarters · filed 2020-05-11
$11.50M
derived: sum of 3 quarters · filed 2020-05-11
$16.96M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$4.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19
$6.93M
derived: sum of 2 quarters · filed 2020-03-19
$12.39M
derived: sum of 3 quarters · filed 2020-03-19
$15.03M
10-K · filed 2020-03-19
2018-09-30$2.59M
10-Q · filed 2019-11-12
$8.05M
derived: sum of 2 quarters · filed 2019-11-12
$10.69M
10-Q · filed 2019-11-12
$14.08M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$5.46M
10-Q · filed 2019-08-16
$8.10M
10-Q · filed 2019-08-16
$11.49M
derived: sum of 3 quarters · filed 2019-08-16
$13.89M
derived: sum of 4 quarters · filed 2019-08-16
2018-03-31$2.64M
10-Q · filed 2019-05-13
$6.03M
derived: sum of 2 quarters · filed 2019-05-13
$8.43M
derived: sum of 3 quarters · filed 2019-05-13
$9.75M
derived: sum of 4 quarters · filed 2019-05-13
2017-12-31$3.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21
$5.80M
derived: sum of 2 quarters · filed 2019-02-21
$7.12M
derived: sum of 3 quarters · filed 2019-02-21
$8.65M
10-K · filed 2019-02-21
2017-09-30$2.40M
10-Q · filed 2018-11-13
$3.72M
derived: sum of 2 quarters · filed 2018-11-13
$5.26M
10-Q · filed 2018-11-13
$6.68M
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30$1.32M
10-Q · filed 2018-08-10
$2.86M
10-Q · filed 2018-08-10
$4.27M
derived: sum of 3 quarters · filed 2018-08-10
$5.69M
derived: sum of 4 quarters · filed 2018-08-10
2017-03-31$1.53M
10-Q · filed 2018-05-14
$2.95M
derived: sum of 2 quarters · filed 2018-05-14
$4.37M
derived: sum of 3 quarters · filed 2018-05-14
$5.10M
derived: sum of 4 quarters · filed 2018-05-14
2016-12-31$1.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28
$2.84M
derived: sum of 2 quarters · filed 2018-03-28
$3.56M
derived: sum of 3 quarters · filed 2018-03-28
$3.88M
10-K · filed 2018-03-28
$3.88M
10-K · filed 2017-04-03
2016-09-30$1.42M
10-Q · filed 2017-11-13
$1.42M
10-Q · filed 2016-11-21
$2.15M
derived: sum of 2 quarters · filed 2017-11-13
$2.47M
10-Q · filed 2017-11-13
$2.47M
10-Q · filed 2016-11-21
2016-06-30$724.00K
10-Q · filed 2017-08-11
$980.38K
10-Q · filed 2016-08-15
$1.04M
10-Q · filed 2017-08-11
$1.30M
10-Q · filed 2016-08-15
2016-03-31$321.00K
10-Q · filed 2017-05-12
$320.57K
10-Q · filed 2016-06-16
2015-12-31$738.23K
10-K · filed 2017-04-03
2015-09-30$222.75K
10-Q · filed 2016-11-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33
Theriva Biologics, Inc. (TOVX)United States$0.011B
Dare Bioscience, Inc. (DARE)United States$0.011B
Azitra, Inc. (AZTR)United States$0.010B-0.81
Medicus Pharma Ltd. (MDCX)$0.010B
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92